An open label, phase 2 study including 72 patients treated with LAG-525, which is an IgG4 mAb for LAG-3, and spartalizumab (PDR001), an anti-PD-1, for advanced solid tumors and hematologic malignancies showed promising activity, especially in neuroendocrine tumors, small cell lung cancer (SCLC), and diffuse large B-cell lymphoma (DLBCL), with a clinical benefit rate at 24weeks (CBR24) of 0.86, 0.27, and 0.804, respectively, meeting its primary endpoint (NCT03365791) (Uboha et al., 2019). Here, STMN1 is linked to small cell lung carcinoma.